SCYX SCYNEXIS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1178253 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY544.0%
TTM net income YoY60.1%
TTM EPS YoY127.8%
Revenue 3-yr CAGR-48.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-126.9%
Net margin-53.5%
FCF margin—
EBITDA margin—
Returns
ROE-21.2%
ROA-17.0%
ROIC (approx.)-52.4%
Asset turnover0.32x
Leverage & solvency
Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.19x
Accruals ratio3.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $20.60M | $3.75M |
| R&D expense | $22.28M | $26.41M |
| SG&A expense | $14.39M | $14.46M |
| Operating income | -$16.07M | -$37.12M |
| Interest expense | $173,000 | $828,000 |
| Pretax income | -$8.61M | -$21.14M |
| Income tax | $0 | $151,000 |
| Net income | -$8.61M | -$21.29M |
| EBITDA | — | -$37.12M |
| EPS (basic) | -0.17 | -0.44 |
| EPS (diluted) | -0.17 | -0.44 |
| Weighted avg. shares (diluted) | 49.93M | 48.51M |
| Balance sheet | ||
| Cash & equivalents | $21.26M | $16.59M |
| Short-term investments | $18.77M | $43.25M |
| Current assets | $40.37M | $72.18M |
| Total assets | $59.03M | $90.64M |
| Current liabilities | $5.73M | $24.10M |
| Total liabilities | $9.65M | $35.57M |
| Shareholders' equity | $49.38M | $55.08M |
| Shares outstanding | 5.44M | 37.97M |
| Cash flow statement | ||
| Operating cash flow | -$5.28M | -$24.01M |
| Investing cash flow | $24.31M | $6.15M |
| Financing cash flow | -$14.17M | -$139,000 |
| Depreciation & amortization | — | $0 |
| Stock-based compensation | $2.85M | $3.35M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.